Approval · Notice of Compliance 586 · 2002
HAVRIX: Notice of Compliance 586
Issued March 22, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 586
- Date
- March 22, 2002
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in manufacturing
- Therapeutic class
- Prophylactic vaccine
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HAVRIX | Not yet assigned | — |
| HAVRIX JR. | Not yet assigned | — |
Medicinal ingredients
- HEPATITIS A VACCINE, INACTIVATED 1,440 UNIT per ML
- HEPATITIS A VACCINE, INACTIVATED 720 UNIT per ML